Exacerbation Prevention and Management of Bronchiectasis

Choi, Joon Young

doi:.0..

Tuberc Respir Dis > Accepted Articles

Review

DOI: https://doi.org/10.4046/trd.2023.0010 [Accepted]
Published online May 10, 2023.

Exacerbation Prevention and Management of Bronchiectasis

Joon Young Choi

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06649, Republic of Korea

Correspondence: Joon Young Choi,
Email: tawoe@naver.com

Received: 25 January 2023 • Revised: 2 April 2023 • Accepted: 3 May 2023

Abstract

Bronchiectasis is characterized by irreversibly damaged and dilated bronchi, which causes significant symptoms, poor quality of life, increased economic burden and mortality rates. Despite increasing prevalence and clinical significance of bronchiectasis, bronchiectasis was previously regarded as an orphan disease, and ideal treatment of this disease have been poorly understood. European Respiratory Society and British Thoracic Society have recently published guidelines to assist physicians in the clinical field. Guidelines and reports suggest comprehensive management including both non-pharmacological and pharmacological treatments. Physiotherapy and pulmonary rehabilitation are one of the most important non-pharmacologic therapies in bronchiectasis patients; long-term inhaled antibiotics and macrolide therapy have gained significant evidences in reducing exacerbation risk in frequent exacerbators. In this review, we summarized recent update on bronchiectasis treatment to prevent exacerbation and management of clinical deteriorations

Key Words: Bronchiectasis, Treatment, Exacerbation, Inhaled antibiotics, Macrolide, Airway clearance therapy, Physiotherapy